EU GMP Annex 1 vs USP <797>
Sterile manufacturing vs sterile compounding — same enemy, different regimes.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
EU GMP Annex 1 (2022) governs the industrial manufacture of sterile medicinal products, built around a formal Contamination Control Strategy. USP <797> governs sterile compounding in pharmacies and healthcare settings in the US. Both fight the same enemy — microbial and particulate contamination of sterile products — but at very different scales, under different legal regimes, and with different oversight.
| ASPECT | EU GMP ANNEX 1 | USP <797> |
|---|---|---|
| Setting | Industrial sterile manufacturing | Pharmacy / healthcare sterile compounding |
| Legal force | EU GMP (binding via directives); manufacturer inspections | USP chapter enforceable through state boards and FDA (via FD&C Act) |
| Organising concept | Contamination Control Strategy (CCS) across the whole facility | Beyond-use dating, categories of compounding, facility/personnel controls |
| Cleanroom framing | Grades A/B/C/D; extensive EM and aseptic-process design | ISO-class primary/secondary engineering controls; segregated compounding areas |
| Scale | Batch manufacturing, large volumes | Patient-specific and small-batch preparations |
| Beyond-use / expiry | Full stability programme sets shelf life | Beyond-use dates by category and conditions |
Follow Annex 1 when you industrially manufacture sterile products — the CCS, grade A/B/C/D design, aseptic process simulation, and EM expectations apply.
Follow USP <797> when you compound sterile preparations in a pharmacy or clinical setting — beyond-use dating, engineering controls, personnel competency, and category-based rules govern.
Same objective, different worlds. Annex 1 is manufacturing GMP with a facility-wide Contamination Control Strategy; USP <797> is compounding practice tuned to pharmacy-scale, patient-specific work. Do not import <797> beyond-use dating into a manufacturing shelf-life claim, and do not expect a compounding pharmacy to run a full Annex 1 CCS — match the regime to the activity, and note the 503B outsourcing-facility middle ground where cGMP applies to compounding at scale.
EU GMP Annex 1 vs USP <797>: frequently asked questions
Common questions on how EU GMP Annex 1 and USP <797> differ and when each applies.
Is USP <797> the compounding version of Annex 1?
Loosely — both target sterile-product contamination — but they are legally and operationally distinct. Annex 1 is industrial manufacturing GMP; <797> is US compounding practice. They share concepts (cleanroom classification, aseptic technique, environmental control) but are not interchangeable.
Which applies to a 503B outsourcing facility?
A 503B outsourcing facility compounds at scale and must follow cGMP — closer to Annex-1-style manufacturing expectations — whereas a 503A pharmacy compounds patient-specific preparations primarily under USP <797> and state board oversight.
What is a Contamination Control Strategy (CCS)?
Introduced prominently in the 2022 Annex 1, a CCS is a documented, holistic view of all the controls (facility, process, equipment, personnel, monitoring) that together prevent contamination, with their effectiveness assessed collectively rather than in isolation.
Do both require media fills?
Both require validation of aseptic processes. Annex 1 mandates aseptic process simulations (media fills) for manufacturing; <797> requires media-fill testing as part of personnel competency and process verification for sterile compounding.